advertisement
Find Articles in:
All
Business
Reference
Technology
News
Lifestyle

Warner Chilcott and Paratek Pharmaceuticals Sign Collaboration Agreement for Novel, Narrow-Spectrum Agents for Acne and Rosacea.

PR Newswire Europe, July, 2007

Content provided in partnership with HighBeam Research

FAJARDO, Puerto Rico and BOSTON, July 9 /PRNewswire/ --

Warner Chilcott Company, Inc. and Paratek Pharmaceuticals, Inc. announced today that the two companies have entered into an exclusive license agreement for the development and commercialization of novel, narrow-spectrum tetracyclines for the treatment of acne and rosacea.

Tetracycline antibiotics are the leading approved systemic treatments of moderate to severe inflammatory acne. Discovered decades ago as broad-spectrum systemic antibiotics, tetracyclines have been shown to be potent anti-acne agents. Paratek has utilized its expertise in chemistry to develop novel narrow-spectrum antibacterial tetracyclines with improved anti-inflammatory activity, tolerability and other properties for the next...

 

BNET TalkbackShare your ideas and expertise on this topic

The following tags are supported in BNET comments:
<b></b> <i></i> <u></u> <pre></pre>

Leave a Reply

  1. You are currently a guest | Login?
advertisement
Go
advertisement
  • Click Here
  • Click Here
advertisement